Kornimate/medical-research-clean huggingface dataset:
laminaria tents versus vaginal prostaglandin in cervical ripening

Conditions: Labor Onset and Length Abnormalities

Summary: mechanical methods used for induction of labor received a great attention nowadays due to the serious side effects of the pharmacological methods. hygroscopic dilators are considered important subtype of these mechanical methods. one of them is laminaria which is a synthetic type of sea algae that induces cervical dilation by absorbing water from the cervix and gradually increasing in thickness. the current study will compare the effectiveness and safety of laminiria and vaginal prostaglandins in induction of labor in women with unfavorable cervix.

a new method for induction of labor to be studied

Eligibility criteria:
inclusion criteria: * pregnant women with: * age 18-45 years. * live fetus with cephalic presentation. * normal non-stress test with reassuring features (baseline heart rate 110-160 beats/min, baseline variability 5-25 beats/minute, and no decelerations) (national institute for health and clinical excellence 2017). * gestational age of 37 weeks or more (middleton et al. 2020). * fetal weight less than 4 kilograms. * bishop score less than 6 (navve et al. 2017). * no labor pains. * no contraindications for vaginal delivery exclusion criteria: * o presence of fetal distress. * presence of thick meconium-stained amniotic fluid * presence of fever, chorioamnionitis, or vaginal bleeding before intervention.
the incidence of aphasia, dysarthria and dysphagia following stroke

Conditions: Acute Stroke

Summary: the objective of the study is to estimate the incidence and recovery of aphasia, dysarthria and dysphagia in an acute setting (first week) with the nihss sub-item scores for language and speech and a dysphagia screening. furthermore, we will evaluate the severity of aphasia, dysarthria and dysphagia in an acute setting (first few days) with standardized measurements (screeling, bnt, nsvo-z, perceptual assessment, masa/fois). to evaluate the effect of early ivt/evt in patients with ischemic stroke on functional outcomes for language and speech via the nihss scale.

study population: patients who are admitted to the acute stroke unit of the university hospital ghent will be recruited. study course: the study has a prospective, observational design, with each participant receiving regular standard of care as follows: patients will undergo a clinical examination by a staff neurologists or the present attending in the emergency room. tailored medical treatment will be given to each patient considering the type of stroke etc. as is standard of care (e.g. thrombolysis and/or thrombectomy for patients with ischemic stroke). patients that are stable enough are transferred to the stroke unit where the neurologist or attending of the unit will reassess all stroke patients. nihss scores will be reported at least at day 2 +/- 1. a dysphagia screening is performed by the stroke unit nurses when the patient arrives at the stroke unit. the scores of the sub-items language and speech of the nihss and the dysphagia screening combined with a general screening by a speech language pathologist will be used to confirm or discard aphasia, dysphagia and dysarthria (incidence). when aphasia, dysarthria and/or dysphagia is confirmed, standardized tests will be performed. for this study, data of the following tests will be included for analysis: screeling and/or bnt (aphasia), nsvo-z and a perceptual assessment (dysarthria), masa and/or the fois (dysphagia). at day 7 +/- 1, nihss scores will be reassessed (recovery in time). the diagnostic assessments and the nihss sub-items speech/language will be used to investigate the severity and recovery of the symptoms in time. reports of the neurological clinical examination at follow-up will be retrospectively investigated if possible for additional information about recovery in time. the total duration of data collection will be approximately 1 week and if possible three months follow-up.

Eligibility criteria:
inclusion criteria: * acute stroke patients admitted at the acute stroke unit at the university hospital (ghent) exclusion criteria: * previous aphasia, dysarthria, dysphagia
preventing conduct disorder in child welfare

Conditions: Behavioral Disorder; Child Maltreatment

Summary: a mixed methods randomized control trial was conducted to test the effectiveness of pathways triple p with child welfare involved families compared to treatment as usual. outcomes tested included parenting behaviors and attitudes, and child behavior problems. 144 families were recruited into the study. data was collected at 4 time points (baseline, 4 months, 9 months, and 18 months). over 70% were retained from baseline to 18 months.


Eligibility criteria:
inclusion criteria: * families with open child protective service case following allegation of child physical abuse or neglect * parent of child between the age of 3 and 12 * child remained in the home following investigation * parent spoke english exclusion criteria: * parent's child could not have chronic medical condition or have a pervasive developmental delay

Keywords: triple p rct parent management training child welfare child behavior problems
an observational cohort study to establish accurate nutrition therapy for critically ill patients

Conditions: Nutrition Therapy for Critical Illness

Summary: 1. demographics data; 2. nutritional evaluation data; 3. all biochemical monitoring data during the study period; 4. all nutritional treatment data will be recorded daily during the study period, including actual calorie intake, protein intake, and the proportion of calorie/protein administered by en and/or pn route. the nutritional treatment protocol will be decided by the attending physician, the investigator will not intervene. 5. a blood sample (5 ml) will be drawn from every patient immediately after they enroll into the study, and the metabolomics of the samples will be analyzed analysis using a combined 800 mhz 1h-nmr-uplc-ms system. the data will then be used to establish metabolic profile baseline. 6. we will establish a sub-group that contains 20 patients (chosen from enrolled patients according to apache ii scores: 10 patients are apache ii scores in 21-30). we will take one blood sample daily during the whole study period. the plasma sample will be used for metabolomics analysis using an 800 mhz 1h-nmr-uplc-ms system. and the data will be used for metabolic dynamic modeling. 7. clinical outcomes data, which include: 1) complications after the operation (intestinal fistula, pancreatic fistula, biliary fistula and sepsis, bleeding, nosocomial infection); 2) death event; 3) icu-stay; 4) length of hospitalization


Eligibility criteria:
inclusion criteria: * age: 18-70 * patients are underwent whipple operation or subtotal gastrectomy and ever admitted to intensive care unit (icu) after the operation * receive parenteral or enteral nutrition \> 3 days exclusion criteria: * has metabolic disorders: diabetes, thyroid disease * pregnant or breastfeeding * the presence of drug or alcohol dependence * the presence of tuberculosis, hiv infection and other acute infectious disease * serious liver, kidney, heart and other vital organ failure
the effectiveness of lower cyclosporine doses for psoriasis

Conditions: Psoriasis

Summary: this study will evaluate whether lower doses of cyclosporine can cause fewer side effects and still produce the same beneficial results that are seen with a standard cyclosporine dose regimen when treating individuals with moderate to severe psoriasis.

psoriasis is a chronic inflammatory skin disease. it is believed to be caused by an overactive immune system that speeds the growth of skin cells. this abnormal skin growth results in patches of inflamed skin, which can itch, crack, and bleed. cyclosporine is an immunosuppressant drug that is used in more severe cases of psoriasis to slow down the growth of skin cells. however, cyclosporine use is associated with several side effects, including kidney damage, high blood pressure, and skin sensitivity. this study will evaluate whether lower doses of cyclosporine can cause fewer side effects and still produce the same beneficial results that are seen with the standard administration of cyclosporine. participants in this study will receive treatment with cyclosporine for up to 30 weeks. study visits will occur every 2 weeks and will include a physical exam, a psoriasis symptom evaluation, blood collection, and various questionnaires on quality-of-life issues. participants will be followed for 2 years.

Eligibility criteria:
inclusion criteria: * good health * exception that has been resistant to psoralen and ultraviolet a radiation (puva), methotrexate, and retinoids * moderate to severe, stable plaque psoriasis * normal organ and marrow function * hiv uninfected exclusion criteria: * topical therapy within 4 weeks of study entry * use of systemic, intralesional, or phototherapy within 1 year of study entry * use of cyclosporine in the past or use of other immunosuppressive medication within 6 months of study entry * inability to be followed or monitored regularly on a weekly basis * poorly controlled hypertension * severe infection, internal malignancy, immunodeficiency, gout, or liver disease * received more than 1,000 treatments of ultraviolet a (uva) * history of allergic reaction attributed to compounds of similar chemical or biological composition to cyclosporine * uncontrolled active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia that would limit study participation * women of childbearing potential and men unwilling to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of the study * pregnant
treatment of hypercholesterolaemia in south asian subjects (iris)

Conditions: Hypercholesterolemia; Dyslipidaemia

Summary: the purpose of this study is to compare the effect of 6 weeks of treatment with rosuvastatin with 6 weeks of treatment with atorvastatin in south asian subjects with hypercholesterolemia.


Eligibility criteria:
inclusion criteria: * fasting low density lipoprotein \& triglyceride levels as defined by the protocol. * self described south asian race * subjects with coronary heart disease or at high risk of coronary heart disease. exclusion criteria: * the use of lipid lowering drugs or dietary supplements after visit 1. * active arterial disease eg unstable angina, or recent arterial surgery * blood lipid levels above the limits defined in the protocol. * uncontrolled hypertension, hypothyroidism, alcohol or drug abuse.

Keywords: cholesterol low density lipoproteins dyslipidaemia rosuvastatin crestor atorvastatin lipitor south asian
clinical study on second-eye pain in cataract surgery

Conditions: Senile Cataract

Summary: the degree of perceived pain in the second-eye surgery of cataract patients is significantly higher than that in the first-eye surgery, which can lead to nervous tension during surgery and affect the surgical outcome and satisfaction. study suggested that in addition to psychological factors, there might be subclinical sympathetic reactions leading to increased pain in the second-eyes, but the objective indicators and clinical relevance are not clear. therefore, it is necessary to study the mechanism of second-eye pain in cataract surgery, and to provide a test index that can effectively predict the degree of intraoperative pain in patients, as an important reference for the development of a suitable time for second eye surgery. this study is based on clinical case studies, recruiting patients with clinically diagnosed binocular age-related cataract and require binocular surgery, to compare the correlation of intraocular inflammatory factors in the second eye and patients' self-pain scores while both eyes' surgery are completed by the same doctor in the same operating room, and the correlation of the change of inflammatory factors and the time interval between the two eyes surgery, to analyze the second-eye subclinical sympathetic reaction changing with the time interval after the first cataract surgery from the molecular biological results. using the latest international anterior segment vascularization optical coherence tomography(oct) scan and optical microvascular imaging(omag) analysis technology to quantify iris blood flow, this study analyzes the iris blood flow density, vascular density and other indicators before and after cataract surgery, and carry out its correlation with the degree of intraocular subclinical sympathetic reaction, providing a rapid, non-invasive objective examination index of the second-eye subclinical sympathetic response.

1. coordination and quality control team: the inspection and audit of this research project will be established mainly by hospital clinical research center staff and assisted by the ophthalmology reading center team; 2. the project team member will accept training before the study begins while unified inspection methods and requirements is established in standard operating procedures. 3. the project team double enter the test data independently and establishes an electronic database. 4. the project team randomly selects the data and repeats the measurements to ensure the accuracy as internal audit regularly.

Eligibility criteria:
inclusion criteria: 1. diagnosed with binocular age-related cataract. 2. both eyes require phacoemulsification and intraocular lens implantation. 3. binocular surgery was performed by the same physician in the same operating room, and the anesthesia and surgical procedures were consistent. 4. patients can fully understand the research purpose, research content, accidents and benefits and risks of the clinical trial, and can make their own decisions on participating or not. exclusion criteria: -
the kidney's response to exercise in heat, and the impact of vitamin b3 on this response

Conditions: Heat Strain; Healthy Volunteer Study; Kidney Dysfunction

Summary: the goal of this clinical trial is to learn about the processes occurring in the kidneys while under heat stress in healthy volunteers. the main questions it aims to answer are: * how do the chemicals produced by the body change under conditions of higher versus lower heat stress? * what role does a specific area of the body's metabolism, known as nad+ metabolism, play in the body's response to heat stress, and can this response be modified by taking vitamin b3?

to answer these questions, researchers will compare the chemical changes in each participant under progressively higher levels of heat stress, and while taking either vitamin b3 or a placebo. this clinical trial will occur in two stages. participants may choose participate in stage 1 only, stage 2 only, or both parts of this clinical trial. during stage 1, participants will exercise using an upper body workout device in a hot and humid environmental chamber for three sessions, each session separated by about a week. * each session, they will be asked to work out at a progressively higher intensity with climate conditions kept the same in the chamber. * more intense exercise produces greater heat stress, resulting in lower, moderate, and higher levels of heat stress exposure across the three sessions. * researchers will see how chemicals in the blood and urine, along with physical measurements like heart rate and body temperature, change across these different levels of heat stress. during stage 2, participants will exercise using the same upper body workout device in the same environmental chamber. they will do this for two sessions, each separated by about a week. * one of the sessions each participant will take vitamin b3, and the other session each participant will take placebo. * heat stress exposure will be the same each session. * researchers will again see how chemicals in the blood and urine, along with physical measurements like heart rate and body temperature, change between sessions with vitamin b3 and sessions with placebo

Eligibility criteria:
inclusion criteria: * healthy volunteer * any race * estimated glomerular filtration rate greater than 90 ml/min/1.73m2 * urine albumin/creatinine ratio less than 30mg/g * nonsmoker * no regular dietary supplements, particularly vitamin b3 * physically active, defined as doing at least 150 minutes of physical activity in an average week exclusion criteria: * medical condition preventing safe participation in exercise during heat * allergy to vitamin b3 * severe food allergies or dietary restrictions that would preclude eating the planned study diet without major modifications

Keywords: nad+ niacinamide vitamin b3 experimental heat strain
an observational study to assess change in disease activity and adverse events in adolescent and adult participants with moderate to severe active crohn's disease (cd) in japan

Conditions: Crohn's Disease

Summary: crohn's disease (cd) is an incurable chronic inflammatory disorder of the gastrointestinal tract. this study will assess how safe and effective upadacitinib is in treating moderately to severely active cd in real world. adverse events and change in disease activity will be assessed. upadacitinib is a drug approved for the treatment of cd. all study participants will receive upadacitinib as prescribed by their study doctor in accordance with approved local label. approximately 240 participants will be enrolled in japan. participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. participants will be followed for up to 64 weeks. there is expected to be no additional burden for participants in this trial. study visits may be conducted on-site or virtually as per standard of care.


Eligibility criteria:
inclusion criteria: * diagnosed with moderately to severely active crohn's disease (cd). * has been prescribed upadacitinib for cd as per most current local approved label after its approval for cd in japan. * within 14 days from the commencement of upadacitinib induction treatment for cd at the participating institution. exclusion criteria: * currently participating in another interventional clinical research. * participants for whom upadacitinib is contraindicated. * has been treated with upadacitinib for cd before and continue treatment with upadacitinib for cd at the participation to this study.

Keywords: crohn's disease upadacitinib
electroacupuncture treatment for those with end stage knee osteoarthritis on a total knee arthroplasty waitlist

Conditions: Knee Osteoarthritis

Summary: a 3-armed pilot randomized controlled trial: electroacupuncture, sham acupuncture and waitlist groups.

the purpose of this study is to determine the efficacy of ea as a treatment strategy in the end stage knee osteoarthritis (koa) population waiting for total knee arthroplasty (tka). the research objectives are to 1. to determine the efficacy of ea to provide pain relief, improve function and quality of life in the end stage koa population who are waiting for tka. 2. to determine if ea is superior to sham ea or waiting list groups in providing pain relief, improving function and quality of life in the end stage koa population who are waiting for tka. outcome measures will be collected from all 3 groups at baseline, mid point, completion and 6 week follow up. participants will be recruited from the concordia joint replacement group in winnipeg, manitoba. inclusion criteria: participants are on a waiting list for tka and do not have a surgical date within 3 months from the start of the study.waiting list will be defined as having had consultation with an orthopaedic surgeon and having accepted an offer a tka. the participants will be a minimum of 45 years old and have a nprs ≥ 5. exclusion criteria: knee pain caused by other disease or injury, arthroscopy within the past year, intra articular injection within the previous 3 months, painful ipsilateral hip oa. participants scheduled for simultaneous bilateral tka or revision will be excluded. medical history: serious acute or chronic disease or psychiatric disorders, blood coagulation disorders. surgical history: implanted cardiac pacemakers, history of valve replacement, previous arthroplasty. other: allergy to needle components, needle phobia, pregnancy

Eligibility criteria:
inclusion criteria: * participants are on a waiting list for tka and do not have a surgical date within 3 months from the start of the study.waiting list will be defined as having had consultation with an orthopaedic surgeon and having accepted an offer a tka. the participants will be a minimum of 45 years old and have a nprs ≥ 5. exclusion criteria: * criteria: knee pain caused by other disease or injury, arthroscopy within the past year, intra articular injection within the previous 3 months, painful ipsilateral hip oa. participants scheduled for simultaneous bilateral tka or revision will be excluded. medical history: serious acute or chronic disease or psychiatric disorders, blood coagulation disorders. surgical history: implanted cardiac pacemakers, history of valve replacement, previous arthroplasty. other: allergy to needle components, needle phobia, pregnancy
physical functioning following total hip arthroplasty

Conditions: Osteoarthrosis, Balance Control, Voluntary Movement Control

Summary: adults suffer from osteoarthrosis of hip joint that willing to participate in the study will be tested with well-established measuring techniques of balance control using force plate before 3 month and 6 month after total knee arthroplasty (tha) in the movement and rehabilitation laboratory at bgu. an automated algorithm will be used to extract standardized stabilogram-diffusion parameters from each of the cop data sets collected during quiet standing. these parameters include diffusion coefficients, critical displacement, critical time and scaling exponents for both lateral and anterior-posterior sway directions (collins \& de luca, 1993). each of the times (before 3 month and 6 month after the tha) in two task conditions (eyes closed and eyes close conditions). participants will be required to stand on the platform 10 times for 30 s for each trial, they will be instructed to sway as little as possible. in addition step execution test and late life function and disability questionnaires will be also examined.


Eligibility criteria:
inclusion criteria: * able to stand safely for 30 seconds * able to walk independently * hip oa prior tha exclusion criteria: * stroke or other neurological diseases * minimal score 24 or higher * blindness

Keywords: balance voluntary stepping function disability fear of falls total hip arthroplasty